The latest news from academia, regulators
research labs and other things of interest
Posted: May 3, 2010
Nanomedicine Firm Nanobiotix Successfully Closes $11 Million Financing Round
(Nanowerk News) Nanobiotix, based in Paris, France, announces the closing of a $ 11 million series-C financing round. The company develops innovative therapeutic products for cancer using nanotechnologies.
Nanobiotix raised US 11 million from a strong new and existing syndicate of investors. CIC Vizille Capital Innovation has led this new round with Masseran Gestion. Existing shareholder have strongly participated in the round, Matignon Technologies, OTC Asset Management, Cap Decisif Management, and Amorçage Rhône-Alpes.
«This successful closing is the recognition of the value of Nanobiotix breakthrough technology NanoXray. This financing will enable us to continue to advance our lead programs through clinical studies. We first plan on reinforcing our scientific /développement team and resources: we are entering our first-in-man clinical study of nanoXray therapeutics with IGR Institut Gustave Roussy, - a Europe leading cancer treatment center - for Soft Tissue Sarcoma as initial indication. First preclinical data are very promising: safety in animals of NBTXR3 - when activated by ionizing radiation has been demonstrated; performance has clearly shown the potential of this product to become a new approach for cancer treatment,” says Dr Laurent Levy, PhD, co-founder and CEO of Nanobiotix, a worldwide pioneer in nanomedicine.
« We are thrilled to be part of this very exciting adventure and pleased to help accelerate the development of a new class of cancer treatment, more effective and less deadly to healthy tissues. Nanobiotix has mastered the critical issues related to NanoXray reproductibility, scalability and stability,” says Karine Lignel; CIC - Vizille Capital Innovation.
Since its creation in 2003, the company has made tremendous progresses and obtained significant results. It has a well balanced pipeline and a unique nanomedicine expertise in developing a very promising therapy for cancer treatment.
“We are confident in the development of Nanobiotix and its technology. We truly believe that is the best risk reward products in biotech field,” says Jerome Snollaerts; Cap Decisif Management.
In parallel to the ongoing clinical developments, Nanobiotix has built an industrial and academic collaborative projects portfolio including research programs and industrial partnering, like Sonodrug with Philips Research or Biotech Corp in Malaysia.
“This is a significant step to the development of nanoXRay and we are excited to be that close to offer a potential alternative to patients,” Patrick Langlois; Chairman of the non executive board.
About NanoXray Platform
NanoXray therapeutic platform is designed to enable the precise destruction of cancer cells made possible by the controlled application of an outside the body energy source, in that case an X-ray. The nanoparticles that comprise the nanoXray platform allow for an extensive combination of therapeutic modalities and malignant pathologies. Nbtxr3, the first product to be developed from the nanoXray pipeline, also is the first-in-class product to be activated by radiotherapy. The intended initial indications for Nbtxr3 are:
Soft Tissue Sarcoma – Hepatic Cancer - Colon cancer - Lung cancer - Pancreatic cancer
Dr Laurent Levy will be attending BIO Chicago, from May 3 to May 6.
Nanobiotix is a leading nanomedicine company combining dramatic advances in nanotechnology and molecular biology to develop nanoXray™ — a technology platform that is expected to be turned ‘on’ and ‘off’ outside the body to selectively treat a variety of cancers safely and noninvasively. Use of nanoXray is intended to resolve radiation therapy’s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of Xray is necessary. After nanoXray nanoparticles accumulate in the target tissues, a standard X-ray is applied that is intended to generate a local therapeutic effect, designed to destroy only the targeted tumor cells. This mechanism suggests total control of the intended therapeutic effect.